Yeast Infection Treatment Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The yeast infection treatment market size has grown strongly in recent years. It will grow from $4.33 billion in 2024 to $4.65 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to increased prevalence of yeast infections, growing awareness about fungal infections, aging population, rise in healthcare expenditure globally, and development and approval of new antifungal medications.

The yeast infection treatment market size is expected to see strong growth in the next few years. It will grow to $5.85 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing adoption of telemedicine for remote consultations, personalized medicine approaches for targeted treatment, emergence of combination therapies for enhanced efficacy, growing emphasis on natural and herbal remedies, and focus on microbiome-based therapies for infection management. Major trends in the forecast period include advancements in genomic research, development of compact and accurate diagnostic equipment, technological advancements in the field of yeast infection diagnosis and treatment, increasing investments in research and development, and strategic partnerships.

The anticipated increase in autoimmune disease prevalence is forecasted to drive the expansion of the yeast infection treatment market in the foreseeable future. Autoimmune diseases involve the immune system mistakenly attacking healthy cells, tissues, and organs, leading to weakened bodily functions and potentially life-threatening complications. Yeast infection treatments play a crucial role in managing and preventing autoimmune disease complications by addressing recurrent yeast infections associated with certain autoimmune syndromes. Additionally, they may modulate the immune response by managing fungal infections in patients with autoimmune conditions. For instance, as of March 2023, the National Institutes of Health reported an estimated 8.4 million global cases of type 1 diabetes (T1DM) in 2021, with 500,000 new cases reported that year. Projections indicate the T1DM population to reach between 13.5 and 17.4 million by 2040. Hence, the increasing prevalence of autoimmune diseases is fostering the growth of the yeast infection treatment market.

Key players in the yeast infection treatment market are concentrating on introducing innovative solutions, such as non-azole oral antifungals, to enhance their competitive position. A non-azole oral antifungal is a medication designed to combat fungal infections without belonging to the azole class. For instance, in December 2022, SCYNEXIS, a US-based biotechnology company, received approval from the United States Food and Drug Administration (FDA) for BREXAFEMME (ibrexafungerp tablets), marking its second indication. BREXAFEMME is a pioneering non-azole oral antifungal, the first FDA-endorsed therapy for treating vaginal yeast infections (vulvovaginal candidiasis, VVC) and reducing the recurrence of VVC. With its broad-spectrum activity, BREXAFEMME provides a novel alternative, addressing the limited treatment options for patients with recurrent VVC and reshaping the yeast infection treatment market landscape. The recommended dosage of BREXAFEMME for VVC treatment is 300 mg (two 150 mg tablets) administered one day apart, totaling 600 mg (four 150 mg tablets) daily.

In March 2023, GlaxoSmithKline Plc, a UK-based biopharma company, entered into a partnership with Scynexis to advance the development of Brexafemme (isavuconazonium sulfate) for treating vaginal yeast infections. Through this collaboration, the availability and accessibility of this innovative treatment are expected to be significantly enhanced, providing substantial benefits for patients with challenging infections caused by resistant fungi. Scynexis, a US-based biotechnology company, specializes in creating innovative therapies for hard-to-treat infections, with a primary focus on fungal infections.

Major companies operating in the yeast infection treatment market report are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi SA, Thermo Fisher Scientific Inc., Abbott Laboratories, AstraZeneca PLC, Bayer AG, Astellas Pharma Inc., Torrent Pharmaceuticals, Catalent Inc., bioMérieux SA, Cipla, Bruker Corporation, Brundavan Laboratories Private Limited, Glenmark Pharmaceuticals Ltd, Zydus Lifesciences, Prestige Consumer Healthcare Inc., CordenPharma International, Synmedic Laboratories, Basilea Pharmaceutica AG, Jubilant Pharmova Limited, Curia Global Inc., Synexis LLC, Manus Aktteva Biopharma LLP.

North America was the largest region in the yeast infection treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the yeast infection treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the yeast infection treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The yeast infection treatment market consists of revenues earned by entities by providing diagnostic testing, personalized treatment plans, telemedicine consultations, educational programs and more. The market value includes the value of related goods sold by the service provider or included within the service offering. The yeast infection treatment market also includes sales of miconazole, terconazole, fluconazole, amphotericin B, itraconazole, and caspofungin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Yeast infection treatment refers to medications utilized to address infections resulting from Candida fungus overgrowth, commonly known as yeast infections or candidiasis. These infections can manifest in various body parts such as the mouth (oral thrush), genitals (vaginal yeast infection), skin, and mucous membranes. The treatments aim to alleviate yeast infection symptoms.

Yeast infection treatment come in different forms such as powders, creams, ointments, tablets, or capsules, and can involve medical treatment or surgery. Indications for these treatments include genital candidiasis, invasive candidiasis, oropharyngeal or esophageal candidiasis (thrush), among others. Administration routes include oral, topical, IV (intravenous), or IM (intramuscular), and the treatments are utilized across various applications such as retail pharmacies, hospital pharmacies, specialty stores, online sales, and more.

The yeast infection treatment market research report is one of a series of new reports that provides yeast infection treatment market statistics, including yeast infection treatment industry global market size, regional shares, competitors with a yeast infection treatment market share, detailed yeast infection treatment market segments, market trends and opportunities, and any further data you may need to thrive in the yeast infection treatment industry. This yeast infection treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.